A case of abiraterone acetate withdrawal

European Urology

Volumn 64, Issue 3, 2013, Pages 517-518

  Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LETTER; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; KALLIKREINS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881144630     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.06.013     Document Type: Letter

References (4)

1. H. Gauthier, G. Bousquet, D. Pouessel, and S. Culine Abiraterone acetate withdrawal syndrome: Does it exist? Case Rep Oncol 5 2012 385 387
2. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 2000 703 706
3. N. Agarwal, G. Sonpavde, and C.N. Sternberg Novel molecular targets for the therapy of castration-resistant prostate cancer Eur Urol 61 2012 950 960
4. A.J. Armstrong, M.A. Eisenberger, and S. Halabi Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer Eur Urol 61 2012 549 559